Catalyst
Slingshot members are tracking this event:
Achillion (ACHN) and Janssen (JNJ) Announce Start of Enrollment for Phase 2b OMEGA-1 Trial Evaluating JNJ-4178 (Odalasvir/Simeprevir/AL-335) in Patients with Treatment-Naive Chronic Hepatitis C Virus Infection (HCV) Without Cirrhosis
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 28, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2b Enrollment Initiation, Omega-1, Jnj-4178, Odalasvir, Simeprevir, Al-335, Treatment-naive, Chronic Hepatitis C Virus Infection, Hcv, Cirrhosis
